Guido Lancman, MD, on Multiple Myeloma Treatments Being Presented at ASH
The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.
In an interview with CancerNetwork®,Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, spoke about the multiple myeloma treatments coming out of the 2020 ASH Annual Meeting & Exposition that he is most excited about.
Transcription:
So, there are a couple of bispecifics that are not targeting BCMA. So, most of the CAR Ts presented to date target BCMA, and same with… several different bispecifics. But there are a couple, one that targets GPRC5D, as well as CD3 on T cells. And then FCRH5 and CD3 as well. So, I think it's very interesting that these are sort of new classes of targets for patients, perhaps who have already received BCMA therapy, and they're showing really excellent response rates, again, in very heavily treated patients.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
